Merck Stock Quotes

Gates Foundation currently holds corporate stocks and bonds in drug companies like Merck, GSK, Eli Lilly, Pfizer, Novartis, and Sanofi.69 Gates also has heavy positions in Gilead, Biogen, AstraZeneca, Moderna, Novavax, and Inovio. The foundation’s website candidly declares its mission to “seek more effective models of collaboration with major vaccine manufacturers to better identify and pursue mutually beneficial opportunities.

Not only was the drug developed with taxpayer money, but its $712 per dose price to the taxpayer is forty times more than Merck’s $17.64 cost of production. Merck, which expects to make $7 billion per year on the new blockbuster, saw its stock price spike on news of the government contract and after President Biden’s televised plug.

Our investment style has been given a name-focus investing-which implies ten holdings, not one hundred or four hundred. The idea that it is hard to find good investments. So concentrate in a few, seems to me to be an obviously good idea. But ninety-eight percent of the investment world doesn't think this way. It's been good for us-and you-that we've done this.What's funny is that most big investment organizations don't think like this. They hire lots of people, evaluate Merck vs. Pfizer and every stock in the S&P 500, and think they can beat the market. You can't do it.

On June 9, 2021 President Biden dutifully reiterated the US government’s commitment to procure approximately 1.7 million courses of the NIAID-funded drug from Merck.81 BARDA collaborated with a confederacy of other shady Defense Department operatives, including the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the Army Contracting Command, on the $1.2 billion purchase. Not only was the drug developed with taxpayer money, but its $712 per dose price to the taxpayer is forty times more than Merck’s $17.64 cost of production. Merck, which expects to make $7 billion per year on the new blockbuster, saw its stock price spike on news of the government contract and after President Biden’s televised plug.

The best way to determine whether changes in stock prices are in fact independent is to find out whether they fall into a normal distribution. Impressive evidence exists to support the case that changes in stock prices are normally distributed. That should come as no surprise. In capital markets as fluid and as competitive as ours, where each investor is trying to outsmart all the others, new information is rapidly reflected in the price of stocks. If General Motors posts disappointing earnings or if Merck announces a major new drug, stock prices do not stand still while investors contemplate the news. No investor can afford to wait for others to act first. So they tend to act in a pack, immediately moving the price of General Motors or Merck to a level that reflects this new information. But new information arrives in random fashion. Consequently, stock prices move in unpredictable ways.